C330005M16Rik Inhibitors
The target protein C330005M16Rik, while specific in nomenclature, exhibits multifaceted roles within cellular signaling. Functionally, C330005M16Rik participates in intricate pathways, orchestrating cellular responses crucial for homeostasis. It is notably involved in modulating MAPK and PI3K signaling cascades, intricately connected networks regulating cell growth, survival, and differentiation. Inhibition of C330005M16Rik involves intricate modulation of these pathways, where various chemicals act upon specific components. For instance, MEK inhibitors like U0126 and Trametinib disrupt the MAPK pathway, impacting downstream effectors and altering cellular responses. PI3K inhibitors such as LY294002 and Wortmannin impede the PI3K/Akt pathway, influencing cellular survival and indirectly affecting C330005M16Rik.
Additionally, multi-kinase inhibitors like Sorafenib and Dasatinib exert broader effects by targeting interconnected signaling pathways, disrupting the delicate balance of cellular processes. The indirect impact on C330005M16Rik is a consequence of altered signaling cascades, illustrating the complexity of chemical interactions within the cellular milieu. In summary, the inhibition of C330005M16Rik involves targeted interference with specific signaling pathways crucial for cellular function. Understanding the intricate interplay of these pathways is essential for devising effective strategies to modulate C330005M16Rik expression and function for potential applications in cellular research and beyond.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual tyrosine kinase inhibitor targeting EGFR and HER2. Inhibits downstream signaling cascades, including PI3K-Akt and MAPK pathways, suppressing cell proliferation and survival. Impacts C330005M16Rik indirectly through altered EGFR/HER2-associated pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Multi-kinase inhibitor targeting RAF, VEGFR, and PDGFR. Blocks MAPK and PI3K pathways, disrupting cell growth and angiogenesis. Indirectly influences C330005M16Rik by modulating interconnected signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor impeding PI3K/Akt/mTOR signaling. Suppresses cell survival and proliferation. Indirectly affects C330005M16Rik through the PI3K pathway, impacting downstream signaling cascades. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Multi-kinase inhibitor targeting ABL, SRC, and c-KIT. Impacts various signaling pathways, including MAPK and PI3K. Alters cellular processes that indirectly affect C330005M16Rik expression and function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor disrupting mTORC1 complex. Suppresses protein synthesis and cell growth. Indirectly influences C330005M16Rik through mTOR-associated pathways, affecting downstream signaling cascades. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor suppressing c-Jun N-terminal kinase activity. Modulates AP-1 transcription factor and downstream targets. Influences C330005M16Rik indirectly by altering JNK-associated signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor impeding p38 signaling. Modulates transcription factors and cytokine production. Indirectly impacts C330005M16Rik by interfering with the p38 MAPK pathway and its downstream effectors. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
PI3K inhibitor blocking PI3K/Akt signaling. Suppresses cell survival and proliferation. Indirectly affects C330005M16Rik by influencing the PI3K pathway and its associated cellular responses. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK1/2 inhibitor targeting the MAPK pathway. Suppresses cell growth and induces apoptosis. Indirectly influences C330005M16Rik by interfering with the MAPK signaling cascade. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $193.00 $510.00 $1072.00 | 4 | |
Multi-kinase inhibitor targeting VEGFR, PDGFR, and other receptors. Modulates angiogenesis and cell proliferation pathways. Indirectly impacts C330005M16Rik by interfering with interconnected signaling cascades. | ||||||